ArticleMolecular medicine reports2020
lncRNA TINCR facilities bladder cancer progression via regulating miR‑7 and mTOR.
Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Bladder cancer: non-coding RNAs and exosomal non-coding RNAs.Functional & integrative genomics · 2024Review
- A risk model based on lncRNA-miRNA-mRNA gene signature for predicting prognosis of patients with bladder cancer.Cancer biomarkers : section A of Disease markers · 2024Article
- Epigenetic and Immunological Features of Bladder Cancer.International journal of molecular sciences · 2023Review
- Identification of novel key regulatory lncRNAs in gastric adenocarcinoma.BMC genomics · 2022Review
- Identification of a three-miRNA panel in serum for bladder cancer diagnosis by a diagnostic test.Translational cancer research · 2022Article
- Article
- lncRNA TINCR Regulates Proliferation and Invasion of Hepatocellular Carcinoma Cells by Regulating the miR-375/ATG7 Axis.Journal of oncology · 2022Article
- Biological functions and clinical significance of long noncoding RNAs in bladder cancer.Cell death discovery · 2021Review
- TINCR inhibits the proliferation and invasion of laryngeal squamous cell carcinoma by regulating miR-210/BTG2.BMC cancer · 2021Article
- Downregulation of TAF9B by miR-7-5p Inhibits the Progression of Osteosarcoma.OncoTargets and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non‑coding RNAs (lncRNAs) have been implicated in various human malignancies, but the molecular mechanism of lncRNA TINCR ubiquitin domain containing (TINCR) in bladder cancer remains unclear. The present study found that the expression of TINCR was significantly increased in bladder cancer tissues and cell lines, when compared with that in adjacent normal tissues and normal urinary tract epithelial cell line SV‑HUC‑1, respectively. Moreover, the high expression of TINCR was associated with tumor metastasis and advanced tumor, node, metastasis stage, as well as reduced overall survival rates of patients with bladder cancer. Further investigation revealed that microRNA (miR)‑7 was negatively mediated by TINCR in bladder cancer cells. Silencing of TINCR expression significantly increased miR‑7 expression and reduced bladder cancer cell proliferation, migration and invasion, while knockdown of miR‑7 expression reversed the inhibitory effects of TINCR downregulation on bladder cancer cells. mTOR was then identified as a target gene of miR‑7 in bladder cancer, and it was demonstrated that overexpression of mTOR reversed the inhibitory effects of miR‑7 on bladder cancer cells. In conclusion, this study suggests that TINCR/miR‑7/mTOR signaling may be a potential therapeutic target for bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.